You just read:

Eisai Enrols Patients in Global Phase III Trial to Evaluate First-line Kisplyx® (lenvatinib) Plus Pembrolizumab or Everolimus Versus Sunitinib in Advanced Renal Cell Carcinoma[1]

News provided by

Eisai

03 Oct, 2016, 00:01 BST